Category: Clients

cbdMD, Inc. (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, today announced the timing for the payment of its declared regular monthly dividend of $0.0667 per share of its 8.0% Series A Cumulative Convertible Preferred Stock (NYSE American: YCBD PR A) for November 2019. The dividend will be payable on November 15, 2019 to holders of record as of November 1, 2019. The dividend will be paid in cash. The November 2019 dividend is the first dividend declared by us on our 8% Series A Cumulative Convertible Preferred Stock following the issuance of these shares in a firm commitment underwritten public offering which closed on October 16, 2019.

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD and NYSE American: YCBD PR A) owns and operates the nationally recognized consumer cannabidiol (CBD) brand cdbMD, whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils and CBD pet products. cbdMD, Inc. is a nationally recognized consumer cannabidiol (CBD) brand whose current products include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, and CBD pet products. cbdMD is also the proud partner with the Big 3 Basketball League, Barstool Sports, Bellator MMA, (a subsidiary of Viacom: NASDAQ:VIA), LifeTime and Nitro Circus. To learn more about cbdMD, Inc. and our comprehensive line of over 100 SKU’s of U.S. produced, THC-free CBD products, please visit: www.cbdmd.com or follow cbdMD on Instagram and Facebook or visit one of the 3,000 retail outlets that carry cbdMD products.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. The information which appears on our website and our social media platforms is not part of this press release.

Vancouver, British Columbia–(Newsfile Corp. – October 22, 2019) – The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that seasoned marketing professional Karla Cheon has been appointed as Vice President, Marketing of Yield Growth, effective October 21, 2019.

Yield Growth Appoints Vice President of Marketing, Karla Cheon.

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6377/48977_PR-LI_Karla.jpg

Cheon has a proven track record as a marketer for successful, growing brands. As a testament to her unique combination of marketing insight, brand-building talent and business acumen, she was selected to lead or partner on the marketing aspects of key strategic growth initiatives at Aritzia during her nearly 15-year tenure at the leading fashion retailer: Aritzia’s expansion into the USA (2007) and Quebec (2013), its eCommerce launch (2012), and its Initial Public Offering (2016). Aritzia is a vertically integrated, innovative design house of exclusive fashion brands. It reported net revenue of $874 million in Fiscal 2019.

In particular, Cheon has deep expertise in eCommerce and digital marketing, two areas of critical importance to the success of any brand. As Marketing Director, Interactive, she developed the content and traffic generation strategy for aritzia.com. Later, as Director, eCommerce Marketing and Online Experience, she was part of the team that built Aritzia’s first eCommerce website and was responsible for creating its award-winning online experience. As part of the IPO team, she also created Aritzia’s first-ever investors website.

“As Yield Growth prepares to launch new brands and expand its existing brands to new markets, Cheon’s marketing prowess will be invaluable,” says Penny White, CEO of Yield Growth.

Cheon holds a Bachelor of Arts degree with a focus on Communication, Culture and Information Technology from Queen’s University. She is eager to apply her marketing know-how in this burgeoning industry.

“As regulations around cannabis-based products come into alignment, there is a tremendous opportunity for brands who can meet both the needs of an increasingly savvy consumer who seeks high-quality, natural products, as well as demonstrate a commitment to acting responsibly,” says Cheon. “Yield’s portfolio is poised to take advantage of this, and I am tremendously excited to be part of shaping these brands.”

About The Yield Growth Corp.

The Yield Growth Corp. is building and operating hemp, cannabis and edible mushroom assets in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. It owns the cannabis wellness brands Urban Juve, Wright & Well and Jack n Jane. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy and Aritzia. Its all natural hemp skin care brand, Urban Juve, has signed distribution agreements in Canada, Columbia, Brazil, Greece and Cypress and through its distributor network has access to over 8,000 retail locations. Urban Juve has been featured in UK Vogue, Vanity Fair UK and Elle Canada and has an alliance with leading online beauty community, ipsy. Yield Growth’s Wright & Well brands are launching a THC/CBD line of topical products in Oregon and a CBD from hemp topicals line in California this fall. Jack n Jane is launching cannabis products in Canada in 2019. Yield Growth is launching a line of edible mushroom wellness products in 2020.

Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It had filed 12 patents to protect its extraction method and formulas. Yield Growth is in revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677

1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well, UJ Beverages, Jack n Jane and Flourish Mushroom products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48977

News by QuoteMedia

SAN MATEO, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”) today announced the addition of Dr. Ari Mackler as the Company’s Chief Scientific Officer. Dr. Mackler brings 20 years of medical affairs, communications, and research experience in pharmaceutical, healthcare, and consumer goods industries.

Prior to joining PLUS, Mackler was vice president of clinical development for The Wonderful Company, where he led health & wellness initiatives to help establish the business as a global branded products leader. He also held previous positions with the multinational pharmaceutical company Merck & Co, the Almond Board of California, the International Tree Nut Council, the Nutritional Research & Education Foundation, and Stem Cell Resource.

Dr. Mackler’s position at PLUS will allow him to pursue research relationships and clinical trials with academic institutions and private partners in an effort to expand and contribute to consumer understanding of cannabis and the benefits it may provide. He will join an existing team of experts at PLUS that includes Michelin-star sous chefs, chemists, and food manufacturing experts who together have helped develop the number one and two best-selling cannabis products in the California¹.

“Dr. Mackler has a long history of helping consumer product companies share a clear and scientifically backed narrative around product benefits. Cannabis is a performance category, and the most successful brands will be those that understand and are able to clearly communicate why their products work. There are few researchers of Dr. Mackler’s caliber in the cannabis industry today, and we believe he will play an invaluable role not only for PLUS, but as a though leader within the industry,” stated Jake Heimark, Co-Founder and CEO.

“I have been intrigued by cannabis for years and saw a huge opportunity to apply my scientific and consumer products background for PLUS to help validate and articulate how their products may help people live better lives,” stated Mackler. “I also believe scientifically-based education is vital to the future of the industry, and PLUS has focused their business processes in a way that ensures science is at the center of their product development DNA.”

_{(1)  Over the last twelve months by units and dollars of retail sales according to BDS Analytics}

Availability

California THC: PLUS cannabis infused edibles are available in over 360 licensed retailers across the state of California.

Nevada THC: PLUS cannabis infused gummies are currently available several Las Vegas dispensaries, including 3 Medmen locations, and are expected to be rolled out to dispensaries across Nevada in the coming weeks.

National Hemp CBD: PLUS recently announced a line of 100% Hemp CBD infused gummies. They are available for purchase at plusproducts.com nationwide.

About PLUS

PLUS is a hemp and cannabis food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable – that begins with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, CA with 80 employees.

For further information contact:

Jake Heimark
CEO & Co-founder
ir@plusproducts.com

Investors:

Blake Brennan
Director of Investor Relations
Blake@plusproducts.com
Tel +1 213.282.6987

Media:

Bill Harrison
Third Street Media Group
bill@thirdstreetmediagroup.com
Tel +1 213.712.8811

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:
This press release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (each, a “forward-looking statement”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur and include, but are not limited to, statements relating to: Dr. Mackler’s pursuit of research relationships and clinical trials with academic institutions and private partners; and the expectation that PLUS cannabis infused gummies are expected to be in dispensaries across Nevada in the coming weeks.

These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the success of the Company’s investments, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of the Company’s products, customer experience and retention, the continued development of adult-use sales channels, managements estimation of consumer demand in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete capital projects and facilities improvements, the ability to expand and maintain distribution capabilities, the impact of competition, the ability of the Company to implement initiatives and the possibility for changes in laws, rules, and regulations in the industry. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

MONTREAL, Oct. 17, 2019 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly- owned subsidiary, Biocannabix (“BCX”), has executed an Agreement (the “Agreement”) to acquire 100% of the shares of Weedsense Inc. (“Weedsense”), a late stage applicant for a Standard Processing and Medical Sales license under the Cannabis Act, for an aggregate purchase price of $2,000,000 subject to the achievement of certain milestones.

Weedsense is a Montreal- based business that will build a wholesale and distribution facility outside of the downtown core. Weedsense will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and will be distributing cannabis and cannabis-derived products directly to medical patients.

Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”). Excess capacity at the facility may be rented out once fully licensed, and Weedsense can and may act as a secured storage facility or third party logistics (“3PL”) partner for other market participants who seek direct access to the Quebec market who are in need compliant storage or pick/pack solutions.

Weedsense has applied for a Standard Processing and a Medical Sales license under the Cannabis Act through Health Canada and has since received a positive Status Update to build the project. The facility will be built out to EU GMP standards and will seek EU GMP certification in the near future.

Dave Shepard, CEO and Co-Founder of Weedsense Inc. stated: “We began the transactional process with Relevium in May for a direct investment and, through the last few months, both parties concluded that a full acquisition was the most beneficial avenue for generating shareholder value as well as executing on the buildup of the Weedsense facility.”

Sasha Asgary, COO and Co-Founder of Weedsense stated: “The intended purpose of Weedsense is to solve some of the major supply chain issues that are prevalent in the cannabis market today which include getting products to the medical and recreational markets.” Mr. Asgary continued: “With Cannabis 2.0 coming into effect today, the already fragmented upstream will be further complicated by a host of new suppliers of derivative products nationwide. We think that, in collaboration with Relevium, Weedsense will be in a position to offer a superior user experience to all potential customer and client verticals be it on a D2C or B2B basis or as a service provider within the industry.”

Aurelio Useche, CEO of Relevium stated: “The acquisition of Weedsense is an important milestone for Relevium and Biocannabix as the acquisition of this late stage applicant will help us accelerate our path in distributing cannabis products within our home market in Canada.” Mr. Useche further stated: “Once the Weedsense facility receives approval from Health Canada, we will be able to hold inventory and distribute any products regulated under the Cannabis Act most notable of which will be the Cannakids^TM products. This will be the beginning of generating significant Canadian revenues under Biocannabix. We are thrilled to have executed this agreement and look forward to working with Dave and Sasha on building out the facility and building up the business.”

Transaction Structure

The aggregate purchase price (the “Purchase Price”) payable by Relevium (the “Purchaser”) to Weedsense (the “Vendor”) is $2,000,000, payable in four performance-based installments.

Upon the execution of the Agreement, Relevium will make an initial payment of $500,000 of the Purchase Price (the “Initial Deposit Amount”) by issuing and delivering an aggregate of 7,142,857 Purchaser Shares.

Subsequent to the Initial Payment, Purchaser will pay the balance of the Purchase Price as follows:

1. On the day of submission of the Site Video Evidence Package to Health Canada, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Second Deposit Amount”);
2. On the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Third Deposit Amount”); and
3. Upon the earlier of (i) the first sale of any cannabis product by the Vendor to any customer, which may include any distributor, wholesaler, retailer or other consumer of cannabis products (the “Date of Commercialization”) and (ii) the first anniversary of the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay the final $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (at the election of the Vendors).

Within 30 days following the first 12 months of operations of Weedsense commencing on the Date of Commercialization, the Purchaser shall cause the Vendor to prepare an accounting of its gross sales during such 12 month period, prepared in accordance with Canadian generally accepted accounting principles applicable to private enterprises (the “Statement of Sales”). Within two Business Days after the preparation of the Statement of Sales, the Purchaser shall deliver the Statement of Sales, and all related supporting and background documentation, to the Vendors. If the gross sales as shown on the Statement of Sales is equal to or greater than $1,250,000.00, the Purchaser shall pay an aggregate of $250,000 in cash.

On the date of the Agreement, the Purchaser shall pay to the Vendor the amount of $10,000 in immediately available funds for the purposes of funding the Vendor’s operating expenses. Commencing in the first month following the date of this Agreement, and continuing through to and including February 2020, the Purchaser shall pay to the Vendor $5,000 per month for the purposes of funding the Vendor’s operating expenses.

By no later than March 1, 2020, the Purchaser shall pay to the Vendor, the amount of $750,000 in immediately available funds for the purposes of funding the build-out of the Facility, including leasehold improvements and other modifications to the Facility, in order for the Vendor to seek to obtain the Cannabis License (the “Facility Build-Out Funds”).

By no later than May 31, 2020, the Vendor shall use its commercially reasonable efforts to submit a Site Video Evidence Package to Health Canada in support of the application for the Cannabis License and thereafter shall use its commercially reasonable efforts to diligently pursue the issuance of the Cannabis License from Health Canada.

The Transaction contemplated in the Agreement will close once the Vendor shall have obtained the Cannabis License from Health Canada and all payments necessary will have been delivered by the Purchaser.

The transaction is subject to regulatory approvals including TSX venture Exchange.

About Weedsense Inc.

Weedsense Inc. is a Montreal (Canada) based business that is seeking to build a wholesale and distribution facility outside of the downtown core.

Weedsense will not be cultivating any cannabis at its facility. The Company will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and distributing directly to medical patients. Patients in the Montreal Metro area may enjoy same day delivery and national clients will enjoy national standard delivery times.

Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”).

Excess capacity at the facility may be rented out. Weedsense can and may act as a secured storage facility or third-party logistics (3PL) partner for other market participants who seek direct access to the Quebec market, need compliant storage or pick/pack solutions.

Weedsense has applied for a Standard Processing and a Medical Sales licenses through Health Canada and has received a positive Status Update to build. The facility will be built out to EU GMP standards.

About Relevium Technologies

Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.

Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, or “would” occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.

Aurelio Useche
President and CEO

For more information about this press release:

Tel: +1.888.528.8687

RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com

News by QuoteMedia

• Alkaline88^® will be taking orders for its CBD products at the upcoming ECRM CBD Food and Beverage Program on November 4-6, 2019 in Cape Coral, Florida.
• Full-scale delivery of topical products expected to begin in January, 2020.

SCOTTSDALE, Ariz., Oct. 17, 2019 (GLOBE NEWSWIRE) — The Alkaline Water Company Inc. (NASDAQ and TSXV: WTER) (the “Company”), a producer of premium bottled alkaline drinking water and flavored water sold under the brand name Alkaline88^®, is pleased to announce the formation of A88 Infused Products Inc., a wholly-owned Nevada corporation (“A88 Infused Products”). A88 Infused Products has developed a variety of topical CBD infused products which include salves, balms, lotions, essential oils, and bath-salts all made with lab-tested full-spectrum hemp.

“We now view the entire CBD market as a tremendous opportunity to further expand our brand and product portfolio in both the ingestibles and the natural beauty and personal care category within the much larger health and wellness space. We believe that our growing national footprint consisting of convenience stores, supermarkets, drug stores, and retailers provide us a unique opportunity to take advantage of this significant emerging market trend. We have already been in discussions with a number of our major retail clients who have been early adopters and are excited about this product expansion,” stated Richard A. Wright, president and chief executive officer of The Alkaline Water Company, Inc.

BDS Analytics estimates that U.S. sales of cannabis and hemp-derived CBD product is expected to surge from $1.9 billion in 2018 to $20 billion by 2024, a compound annual growth rate of 49%. According to their research, there is substantial consumer interest in the consumables (tinctures, pills, beverages, food) and Topicals (creams, balms, salves) formats, despite the current low consumer penetration rate. In addition, many major national retailers (CVS, Walgreens, Rite Aid, Sprouts, Whole Foods, Ulta, GNC Holdings, Designer Brands, Urban Outfitters, and Neiman Marcus) have been early adopters of CBD topical products and have introduced various product lines in select markets.

Wright further added, “Our recent introduction of CBD ingestibles has generated strong interest from our major U.S. retail clients. This speaks highly of the brand integrity we have built with our flagship product, Alkaline88^®. We knew CBD topicals was the next natural extension for the Alkaline88^® brand based on the product specific knowledge we acquired from working with Centuria Foods Inc. Over the past several months, we have teamed up with one of the foremost developer and manufacturer of high-performance and authentically natural beauty and personal care products. This established partner has been behind the scenes of many of the world’s most successful, natural, organic, and CBD brands, ranging from Food/Drug/Mass to ultra-premium.”

New Alkaline88^® topical products developed with lab-tested full-spectrum hemp include:

• CBD infused Soothing Salve – 100% natural calming CBD muscle salve infused with luxurious oils and butters to help soothe and comfort irritated, sore muscles.
• CBD infused Lip Balm – 100% natural, made with coconut oil and cocoa butter, ingredients work to moisturize and hydrate lips for all-day comfort.
• CBD infused Hydrating Body Lotion – 100% vegan and cruelty-free body lotion for all skin types packed with shea butter and aloe vera to moisturize, hydrate, and soothe skin for all-day comfort.
• CBD infused Hydrating Hand Lotion – 100% vegan and cruelty-free, this rich nutrient-dense hand and foot cream contain whipped shea Butter and luxurious oils and extracts, which help to deeply nourish and moisturize hands and feet, leaving them soft and supple.
• CBD infused Essential Oil Roller – 100% natural, vegan, and cruelty-free ready for use, concentrated blend of 100% pure essential oils, perfectly balanced with fractionated coconut oil.
• CBD infused Bath Salts – 100% vegan and cruelty-free bath salt formula combines the therapeutic properties of Epsom salts and rejuvenating menthol and essential oils, for the ultimate relaxing experience.

Photos of the new CBD infused product line can be viewed here:
https://www.globenewswire.com/NewsRoom/AttachmentNg/193df781-fae2-4786-abae-0e04794fc4e6
https://www.globenewswire.com/NewsRoom/AttachmentNg/39701105-1579-4776-a3f5-0d6511701002

The Company intends to comply in full with all federal, state, and local laws, rules and regulations as the Company develops its CBD-infused products. The Company will not pursue the commercial production or sale of CBD-infused products until legally permitted. The Company is closely watching and responding to all regulatory developments within the FDA and in each individual U.S. state, and plans to launch its CBD infused products accordingly.

About Centuria Foods Inc. 

Since 2014, Centuria Foods has been producing the safest, highest quality CBD oil in the industry. Prior to the legalization of Hemp and CBD production via the industry-changing 2018 Farm Bill, Centuria Foods was the only legal CBD producer in the U.S., having approvals from the Department of Homeland Security, as well as the Customs and Border Protection. Centuria remains at the forefront of the CBD industry as it continues its meteoric growth under the legal framework of the 2018 Farm Bill. For more information on Centuria visit https://centuriafoods.com/

About The Alkaline Water Company Inc.

The Alkaline Water Company Inc. (NASDAQ and TSXV: WTER) is a leading producer of premium bottled alkaline drinking and flavored water sold under the brand name Alkaline88^®. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88^® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes. The Company recently announced a broad line of CBD infused products which include ingestibles and topical products. For its ingestibles line, the A88 Infused Beverage Division Inc. produces CBD infused drinks, beverage shots, tinctures, capsules, and powder packs. For its topicals line, A88 Infused Products Inc. produces salves, balms, lotions, essential oils, and bath-salt all made with lab-tested full-spectrum hemp. The Alkaline Water Company Inc. is currently pursuing a national multi-channel, mass-market expansion strategy with a direct-to-warehouse model and co-packaging facilities that are strategically located 600 miles within 95% of the U.S. population. Founded in 2012, the Company is headquartered in Scottsdale, Arizona. To learn more about The Alkaline Water Company, please visit www.thealkalinewaterco.com or connect on Facebook, Twitter, Instagram or LinkedIn.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements.” Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the following: the statement relating to taking orders for the Company’s CBD products at the upcoming ECRM CBD Food and Beverage Program on November 4-6, 2019 in Cape Coral, Florida; the statement that full-scale delivery of topical products expected to begin in January, 2020; the statement that the entire CBD Market is a tremendous opportunity to further expand the Company’s brand and product portfolio in both the ingestibles and the natural beauty and personal care category within the much larger health and wellness space; the Company’s belief that the Company’s growing national footprint consisting of convenience stores, supermarkets, drug stores, and retailers provides the Company a unique opportunity to take advantage of the significant emerging market trend relating to the CBD market; and that BDS Analytics estimates that U.S. sales of cannabis and hemp-derived CBD product is expected to surge from $1.9 billion in 2018 to $20 billion by 2024, a compound annual growth rate of 49%.

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that the Company will receive all necessary regulatory approvals for the production and sale of CBD-infused products; that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will be an expansion into new e-commerce, home delivery, convenience, and healthy food channels; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products, including products containing hemp/CBD; the fact that consumers may not embrace and purchase any of the Company’s CBD-infused products; the fact that the Company may not be permitted by the FDA or other regulatory authority to market or sell any of its CBD-infused products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; the fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply-chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact that consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; and competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov, and on the SEDAR, available at www.sedar.com.

The Alkaline Water Company Inc.

Richard A. Wright
President and CEO
800-923-1910
investors@thealkalinewaterco.com

Media

Jessica Starman
888-461-2233
jessica@elev8newmedia.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Alkaline88 CBD Product Portfolio – Topicals and Ingestibles

The Alkaline Water Company

Alkaline88 CBD Topicals Product Portfolio

The Alkaline Water Company

News by QuoteMedia

Vancouver, British Columbia–(Newsfile Corp. – October 11, 2019) – Next Green Wave Holdings Inc. (CSE: NGW) (OTCQX: NXGWF) (“Next Green Wave”, “NGW” or the “Company”) is pleased to announce that it is processing its third cannabis harvest that will be sold for consumption as premium whole flower product, through its partner brands at selected dispensaries throughout California. The cannabis grown by NGW has consistently passed strict category three testing (CAT3) and meets all premium standards for the California market.

SDC cannabis products now available at Columbia Care

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6127/48696_nextgreenwave.jpg

Next Green Wave is continuing to build out its distribution strategy to deliver value to top tier dispensaries through its growing brands and products. Similar to a pharmaceutical distribution model, this will allow the company to bypass third party distributors, improve operational efficiency and deliver direct to the retailer. We are proud to announce that Columbia Care dispensaries have now been added to our growing network.

“In less than 6 months since opening our flagship facility, we have completed three harvests of premium quality, high THC cannabis, as well as fully scaled the entire space. As such, the facility is now in a perpetual harvest cycle in which roughly 14% of the flowering space is being processed every 10-14 days. At the same time, we are fortunate to have recently sourced and hired key additional talent to support and facilitate our expanding operations. We are now cultivating at full capacity and our employees will continue to play a significant role as we expand our market share by supplying the highest quality cannabis products to market in a timely fashion,” stated CEO Mike Jennings.

One of fourteen 1,300 sq ft growing rooms, two rooms will be harvested every 10-14 days

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6127/48696_f5e3f5d274b57885_003full.jpg

NGW is a fully integrated premium cannabis producer with 8 legacy brands and over 45 products marketed through its WEARESDC brand house. Based in Coalinga, California the company owns and operates a 35,000 sq ft state-of-the-art cultivation facility and is currently expanding extraction and other operations on its cannabis zoned campus. NGW has a seed library of over 120 cannabis strains which include multiple award-winning genetics and cultivars and is developing its nursery cloning operations with bio-tech leader Intrexon. To find out more visit us at www.nextgreenwave.com or follow us on Twitter, Instagram, or LinkedIn.

On behalf of the board,

Michael Jennings, CEO
Next Green Wave Holdings Inc.

For more information regarding Next Green Wave, contact:
Caroline Klukowski
VP Corp. Development
Tel: +1 (778) 589-2848
IR@nextgreenwave.com

Next Green Wave Forward Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the risk factors included in the preliminary prospectus, including without limitation dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete construction of its proposed facilities in a timely manner; engaging in activities which currently are illegal under US federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; NGW’s limited operating history and lack of historical profits; reliance on management; NGW’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of Tranche 1 and Tranche 2 of the Notes; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. Readers are encouraged to the review the section titled “Risk Factors” in NGW’s prospectus. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although NGW has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. NGW no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48696

News by QuoteMedia

VANCOUVER, British Columbia, Oct. 10, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that its wholly owned subsidiary Flourish Mushroom Labs Inc. has completed the acquisition, announced on September 24, 2019, of a catalogue of mushroom formulas as the foundation of a mushroom edibles business.

The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer’s choice. The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees.

The global edible mushrooms market is expected to grow at a CAGR of 7.95% to grow to US$62 billion by 2023, increasing from US$42 billion in 2018, according to a report by Research and Markets. Grand View Research reports that the global healthy snacks market size is expected to reach US$32 billion by 2025.

According to healthline.com, studies have shown that cordyceps (medicinal mushrooms) boost exercise performance, improve memory and sex drive, slow growth of tumors and can improve heart health. A study published in The Journal of Alzheimer’s Disease, as reported by the BBC, found that a unique antioxidant present in mushrooms could have a protective effect on the brain, and the more mushrooms people ate, the better they performed on tests of thinking and processing.

“Learning and memory are the core cognitive functions of the human brain,” says Penny White, Yield CEO. “With a rapid decline of age affecting the population, cognitive deficit is leading to many neurological diseases. Flourish recognizes the early prevention needed for declining learning and memory to conduct research into creating edible products combining the mushroom medicine for a broad potential market.”

Included in the acquisition is know-how and research related to edible mushrooms that could be used in the formulations and various health benefits that can accrue to people eating those mushrooms, as determined by researching data published from clinical trials and from knowledge of Chinese, Tibetan and Ayurvedic medicine. The varieties of mushrooms to be used in the formulations include Lion’s Mane, Turkey Tail, Reishi, Shitake, Chagas, Cordyceps and other wild varietals. The research and data on health benefits are included in the acquisition by Flourish.

Flourish purchased the formulations and all know-how and data related to the formulations with the issuance of 120,000 common shares of Yield Growth at a deemed value of $0.25 per share.

According to The New York Times, on September 4, 2019 Johns Hopkins Medicine announced the launch of the Center for Psychedelic and Consciousness Research, to study compounds like LSD and psilocybin for a range of mental health problems, including anorexia, addiction and depression. The center is the first of its kind in the country, established with $17 million in commitments from wealthy private donors and a foundation. CNBC says that investors are starting to bet big on psychedelic medicine with ATAI Life Sciences completing a $40 million round in March 2019 at a $240,000,000 valuation.

By mutual agreement Yield Growth is not proceeding with any investment into Absolem Health Corp.

About The Yield Growth Corp.

The Yield Growth Corp. is building and operating hemp, cannabis and other wellness assets in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy and Aritzia. Its all-natural hemp skin care brand, Urban Juve, has signed distribution agreements in Canada, Columbia, Brazil, Greece and Cypress and through its distributor network has access to over 8,000 retail locations. Urban Juve has been featured in UK Vogue, Vanity Fair UK and Elle Canada and has an alliance with leading online beauty community, ipsy. Yield Growth’s Wright & Well brands are launching a THC/CBD line of topical products in Oregon and a CBD from hemp topicals line in California this fall.

Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It had filed 12 patents to protect its extraction method and formulas. Yield Growth is in revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well and UJ Beverages products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/287af419-ba73-4828-901e-ce2b4b26e5f6

The Yield Growth Corp – Flourish Mushroom Labs Inc

Varieties of mushrooms to be used in the edible formulations include Lion’s Mane, Turkey Tail, Reishi, Shitake, Chagas, and Cordyceps, among other wild varietals

News by QuoteMedia

TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”) has closed a credit agreement (the “Credit Facility”) with a top 5 Canadian Schedule 1 bank (the “Bank”) for an aggregate $38.7 million. The Credit Facility was upsized from the previously announced committed term sheet of $20.0 million, and is comprised of a revolving term facility, a non-revolving term facility and a non-revolving delayed draw term facility.

“With the successful upsizing of our Credit Facility and the proceeds from our recent $75 million bought deal equity offering, we have strengthened our balance sheet and our ability to execute our global business plan to efficiently seize the growth opportunities before us,” said Pat McCutcheon, Chief Executive Officer of MediPharm Labs. “In particular, this enlarged facility will enhance liquidity and support the delivery of our stated Canadian and Australian capex strategy, to ramp up of production capacity to meet contracted and expected demand for our new product classes.”

The Company’s $38.7 million Credit Facility was upsized from the previously announced committed term sheet of $20.0 million. The revolving term facility is for up to $25.0 million subject to the Company’s borrowing base, can be drawn in Canadian or Australian dollars, has a 1-year term and is to be used for Canadian and Australian working capital. The $5.7 million non-revolving term facility was fully drawn on closing, has a 3-year term and was used to refinance and reduce the interest expense of an existing mortgage. The non-revolving delayed draw term facility of up to $8.0 million has a 3-year term and is to be used to fund capital expenditures.

“MediPharm Labs has distinguished itself in the cannabis industry as a diverse, profitable, risk-managed growth company,” said Mr. McCutcheon. “The closing of the Credit Facility required extensive due diligence of our current production site and capabilities, along with a detailed review of our Company’s expected revenue growth, liquidity and regulatory compliance. The Credit Facility will add to our strong balance sheet to assist us in executing on our business strategy and accelerating our domestic and international expansion strategies.”

The Credit Facility will bear interest at the Bank’s prime lending rate plus a certain per cent per annum dependent upon the Company’s debt to EBITDA ratio. The Credit Facility has a first ranking general security interest in the Company’s assets and can be repaid without penalty.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-grade cannabis oil and concentrates and advanced derivative products utilizing cGMP (current Good Manufacturing Practices) designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with 5 primary extraction lines having 300,000 KG of annual processing capacity to deliver pure, safe and precisely-dosed cannabis products for its customers. Through the Company’s wholesale, private and white label platform, MediPharm Labs formulates, processes, packages and distributes active pharmaceutical ingredients and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 KG of annual processing capacity.

For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, capital expenditures for the Barrie and Australian facilities, ramp up of production capacity, expected demand for new product classes, execution of our business strategy, accelerating our domestic and international expansion strategies, the completion of the Australian facility and the processing capacity of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

News by QuoteMedia